Slater Technology Fund is a seed-stage venture investor providing capital for early-stage technology startups in Rhode Island that show high-growth promise.

Slater Technology Fund

RightHill Ventures provides venture capital and support to early-stage technology companies commercializing research and development from university ecosystems, partnering with institutions such as Brown and the University of Rhode Island.

RightHill Ventures

The Slater Technology Fund is an evergreen not-for-profit seed fund supporting new venture development in Rhode Island. More than two decades ago, Slater launched a platform for seed-stage investing in Rhode Island; today, the organization remains the most active seed-stage investor in the state. Slater has invested in hundreds of technology ventures in the region, achieving multiple exits while also generating economic impact returns in the form of high-wage jobs.

Very excited to have thoughtful venture investors joining us on our journey
Octagon Therapeutics

Slater joined forces with top #AI brains from #BrownUniversity last night. We had a blast discussing #neuralnetworks and #largelanguagemodels models over contemporary cuisine while polishing our AI strategy with this illustrious group: 

George Karniadakis, Brown Professor of Applied Mathematics & Engineering
Jason Harry, Brown Professor of the Practice of Technology and Entrepreneurship
Milan Kocic, Head of Sixth Sense Open Innovation Platform
Matthew Wall, Owner, Oculus Technologies Corporation
Carsten Eickhoff, Professor at the University of Tübingen
Leonard Gleyzer, Brown Applied Math PhD Candidate
Brian Demers, Brown Technology Innovations

Nothing artificial about the opportunity here: a target-rich environment for physics-based problems 💡 

Cc: Thorne Sparkman, Bob Chatham, RightHill Ventures

#RI.-based Bolden Therapeutics, Inc. secures $1.5M in pre-seed #convertible note funding. This financing provides important support to enable Bolden to advance its preclinical development of antisense #oligonucleotides to promote #neurogenesis.

The round was led by Resolute Venture Partners, and included investments from Slater Technology Fund, Lifespan Vision Ventures, and multiple angel investors.

Bolden’s scientific co-founders, Dr. Justin Fallon and Dr. Ashley Webb have identified a key molecular pathway to stimulate neural stem cells to #promote the birth of new neurons (neurogenesis) in the #adult brain.

Bolden Therapeutics, Inc., is a #biotechnology company developing first-in-class therapeutics to promote #neurogenesis for the potential treatment of central nervous system illnesses such as Alzheimer’s disease.

Bolden Therapeutics Resolute Venture Partners I, LLC Slater Technology Fund Lifespan Vision Ventures Justin Fallon 

To share your startup story write us on - contact@startuprise.io

#boldentherapeutics #funding #startup

BOLDEN THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS

https://lnkd.in/eaSjfvb5

Learn more about our portfolio company, Lenoss Medical, and their OsteoPearl through Slater Technology Fund's Q&A. 

In this interview, Founder, President and CEO, Dom Messerli, MBA, dives into problems the OsteoPearl solves, product development, target market, company milestones and advice for entrepreneurs.

#osteoporosis #healthcare #healthcareinnovation #productdevelopment #fracture

News Flash!

The lightning experts at Arctura have teamed up with the industry-leading coatings manufacturer, Mankiewicz Coatings LLC, to provide a new product that will enhance the performance of wind turbine lightning protection systems.

https://lnkd.in/eBFX8Z7r

Metric
Company Name	Slater Technology Fund	RightHill Ventures
Symbol
MSH ID	COM:SLATERFUND	VC:RIGHTHILL
Market	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Financial Services & Finance
Industry	Venture Capital	Venture Capital
Country	US	US
Stage
Employee Count	20
Website	slaterfund.com	righthill.vc
LinkedIn	slater-technology-fund
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

SLAT

COM:SLATERFUND

Slater Technology Fund

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue